NASDAQ:XERS - Xeris Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.49 +0.04 (+0.32 %)
(As of 05/23/2019 01:14 AM ET)
Previous Close$12.45
Today's Range$12.2122 - $12.73
52-Week Range$8.67 - $27.98
Volume144,594 shs
Average Volume222,396 shs
Market Capitalization$336.48 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that is in Phase II clinical trials for the treatment of congenital hyperinsulinism, post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, and hypoglycemia-associated autonomic failure, as well as for treating hypoglycemia associated with intermittent and chronic conditions, and bi-hormonal artificial pancreas closed-loop systems. In addition, it develops continuous subcutaneous glucagon infusion system of ready-to-use glucagon; ready-to-use diazepam formulation, which is in Phase I clinical trial for the treatment of acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is in pre-clinical stage for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.

Receive XERS News and Ratings via Email

Sign-up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XERS
CUSIPN/A
CIKN/A
Phone844-445-5704

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.46 million
Book Value$3.98 per share

Profitability

Net Income$-60,080,000.00
Net Margins-2,997.96%

Miscellaneous

Employees90
Market Cap$336.48 million
Next Earnings Date8/12/2019 (Estimated)
OptionableNot Optionable

Xeris Pharmaceuticals (NASDAQ:XERS) Frequently Asked Questions

What is Xeris Pharmaceuticals' stock symbol?

Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS."

How were Xeris Pharmaceuticals' earnings last quarter?

Xeris Pharmaceuticals Inc (NASDAQ:XERS) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($1.07) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.76) by $0.31. The firm earned $0.25 million during the quarter, compared to the consensus estimate of $0.30 million. Xeris Pharmaceuticals had a negative net margin of 2,997.96% and a negative return on equity of 75.93%. View Xeris Pharmaceuticals' Earnings History.

When is Xeris Pharmaceuticals' next earnings date?

Xeris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August 12th 2019. View Earnings Estimates for Xeris Pharmaceuticals.

What price target have analysts set for XERS?

4 brokerages have issued 12 month price objectives for Xeris Pharmaceuticals' shares. Their predictions range from $23.00 to $27.00. On average, they expect Xeris Pharmaceuticals' stock price to reach $24.50 in the next twelve months. This suggests a possible upside of 96.2% from the stock's current price. View Analyst Price Targets for Xeris Pharmaceuticals.

What is the consensus analysts' recommendation for Xeris Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xeris Pharmaceuticals.

What are Wall Street analysts saying about Xeris Pharmaceuticals stock?

Here are some recent quotes from research analysts about Xeris Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based in Chicago, United States. " (1/12/2019)
  • 2. Mizuho analysts commented, "We continue to see Xeris’ glucagon rescue pen as a superior option for the treatment of severe hypoglycemia from a product profile perspective, as we believe there is a higher probability of successfully delivering the full dose to the patient in an emergency situation. Management believes the product could do much better than a 50% market share." (12/4/2018)

Has Xeris Pharmaceuticals been receiving favorable news coverage?

Press coverage about XERS stock has been trending somewhat negative recently, according to InfoTrie. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Xeris Pharmaceuticals earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Who are some of Xeris Pharmaceuticals' key competitors?

What other stocks do shareholders of Xeris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Pharmaceuticals investors own include Pareteum (TEUM), TG Therapeutics (TGTX), Verastem (VSTM), Abeona Therapeutics (ABEO), Cytori Therapeutics (CYTX), Flexion Therapeutics (FLXN), GlycoMimetics (GLYC), Ocular Therapeutix (OCUL), Omeros (OMER) and Progenics Pharmaceuticals (PGNX).

Who are Xeris Pharmaceuticals' key executives?

Xeris Pharmaceuticals' management team includes the folowing people:
  • Mr. Paul R. Edick, Pres, CEO & Chairman (Age 63)
  • Mr. Barry M. Deutsch, Chief Financial Officer (Age 54)
  • Mr. John P. Shannon, Exec. VP & COO (Age 57)
  • Dr. Steven J. Prestrelski, Co-Founder & Chief Scientific Officer (Age 55)
  • Ms. Allison Wey, Sr. VP of Investor Relations & Corp. Communications

When did Xeris Pharmaceuticals IPO?

(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Who are Xeris Pharmaceuticals' major shareholders?

Xeris Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (11.14%), FMR LLC (11.00%), BlackRock Inc. (6.65%), ArrowMark Colorado Holdings LLC (5.20%), Geode Capital Management LLC (1.00%) and Northern Trust Corp (0.89%). Company insiders that own Xeris Pharmaceuticals stock include Beth Hecht, James E Flynn, Palmetto Partners, Ltd, Paul R Edick, Redmile Group, Llc and Steven Prestrelski. View Institutional Ownership Trends for Xeris Pharmaceuticals.

Which institutional investors are buying Xeris Pharmaceuticals stock?

XERS stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., ArrowMark Colorado Holdings LLC, FMR LLC, Redmile Group LLC, Geode Capital Management LLC, Northern Trust Corp, Morgan Stanley and Pentwater Capital Management LP. Company insiders that have bought Xeris Pharmaceuticals stock in the last two years include Beth Hecht, James E Flynn, Palmetto Partners, Ltd, Paul R Edick and Redmile Group, Llc. View Insider Buying and Selling for Xeris Pharmaceuticals.

How do I buy shares of Xeris Pharmaceuticals?

Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Xeris Pharmaceuticals' stock price today?

One share of XERS stock can currently be purchased for approximately $12.49.

How big of a company is Xeris Pharmaceuticals?

Xeris Pharmaceuticals has a market capitalization of $336.48 million and generates $2.46 million in revenue each year. The company earns $-60,080,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. Xeris Pharmaceuticals employs 90 workers across the globe.

What is Xeris Pharmaceuticals' official website?

The official website for Xeris Pharmaceuticals is http://www.xerispharma.com/.

How can I contact Xeris Pharmaceuticals?

Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at [email protected]


MarketBeat Community Rating for Xeris Pharmaceuticals (NASDAQ XERS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  90
MarketBeat's community ratings are surveys of what our community members think about Xeris Pharmaceuticals and other stocks. Vote "Outperform" if you believe XERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel